StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) stock

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)

Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%

Nurix Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Nurix Therapeutics's R&D Expenses for the twelve months ending Aug 31, 2026 was $334.07M, up 11.0% year over year. For fiscal 2025 it was $316.90M, up 43.0% from the year before. The highest annual figure on record is $316.90M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Nov 30, 2025$316.90M+43.0%
FY2024Nov 30, 2024$221.63M+17.2%
FY2023Nov 30, 2023$189.15M+2.5%
FY2022Nov 30, 2022$184.50M+58.5%
FY2021Nov 30, 2021$116.43M+75.1%
FY2020Nov 30, 2020$66.49M+47.7%
FY2019Nov 30, 2019$45.03M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ3 2026Aug 31, 2026$79.26M-8.0%
Q2 FY2026CQ2 2026May 31, 2026$87.65M+12.2%
Q1 FY2026CQ1 2026Feb 28, 2026$84.14M+20.8%
Q4 FY2025CQ4 2025Nov 30, 2025$83.02M+23.5%
Q3 FY2025CQ3 2025Aug 31, 2025$86.12M+55.2%
Q2 FY2025CQ2 2025May 31, 2025$78.10M+59.6%
Q1 FY2025CQ1 2025Feb 28, 2025$69.66M+39.3%
Q4 FY2024CQ4 2024Nov 30, 2024$67.22M+35.2%
Q3 FY2024CQ3 2024Aug 31, 2024$55.48M+15.9%
Q2 FY2024CQ2 2024May 31, 2024$48.92M+6.9%
Q1 FY2024CQ1 2024Feb 29, 2024$50.01M+9.1%
Q4 FY2023CQ4 2023Nov 30, 2023$49.71M+7.8%
Q3 FY2023CQ3 2023Aug 31, 2023$47.86M+0.2%
Q2 FY2023CQ2 2023May 31, 2023$45.76M-3.6%
Q1 FY2023CQ1 2023Feb 28, 2023$45.82M+6.2%
Q4 FY2022CQ4 2022Nov 30, 2022$46.11M+26.2%
Q3 FY2022CQ3 2022Aug 31, 2022$47.76M+54.5%
Q2 FY2022CQ2 2022May 31, 2022$47.49M+82.7%
Q1 FY2022CQ1 2022Feb 28, 2022$43.14M+87.5%
Q4 FY2021CQ4 2021Nov 30, 2021$36.53M+78.7%
Q3 FY2021CQ3 2021Aug 31, 2021$30.91M+63.2%
Q2 FY2021CQ2 2021May 31, 2021$25.99M+83.8%
Q1 FY2021CQ1 2021Feb 28, 2021$23.00M+77.4%
Q4 FY2020CQ4 2020Nov 30, 2020$20.45M+59.4%
Q3 FY2020CQ3 2020Aug 31, 2020$18.94M+72.0%
Q2 FY2020CQ2 2020May 31, 2020$14.14M–
Q1 FY2020CQ1 2020Feb 29, 2020$12.97M–
Q4 FY2019CQ4 2019Nov 30, 2019$12.82M–
Q3 FY2019CQ3 2019Aug 31, 2019$11.01M–

More Nurix Therapeutics figures

See a number that looks wrong?